in stent restenosis snowmass 2017 final final [read-only]...occlusive 4.2014 1 bms 8.2014 poba...
TRANSCRIPT
![Page 1: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/1.jpg)
O. Hlinomaz
ICRC, St. Anne Univ. Hosp., Brno, Czech Rep.Bulgarian Cardiac Institute, Varna, BulgariaBulgarian Cardiac Institute, Varna, Bulgaria
![Page 2: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/2.jpg)
![Page 3: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/3.jpg)
•• neointimalneointimal hyperplasiahyperplasia•• neointimalneointimal hyperplasiahyperplasia
•• 2020--35%35% afterafter BMS, 5BMS, 5--10%10% afterafter DESDES•• 2020--35%35% afterafter BMS, 5BMS, 5--10%10% afterafter DESDES
•• treatmenttreatment-- locallocal aplicationaplication ofof antiproliferativeantiproliferative•• treatmenttreatment-- locallocal aplicationaplication ofof antiproliferativeantiproliferativedrugsdrugs::
-- drugdrug--elutingeluting stentsstents (DES)(DES)-- drugdrug--elutingeluting stentsstents (DES)(DES)
-- drugdrug--elutingeluting baloonsbaloons (DEB)(DEB)
![Page 4: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/4.jpg)
![Page 5: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/5.jpg)
![Page 6: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/6.jpg)
OcclusiveOcclusive
4.2014 1 BMS8.2014 POBA9.2014 1 DES9.2014 1 DES4.2015 1 DES, DEB9.2015 1 DES, DEB4.2016 2 DEB2.2017 2 DES, DEB2.2017 2 DES, DEB
![Page 7: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/7.jpg)
stststst
•• eeffectffect ofof BMSBMS--ISRISR treatmenttreatment by PEBby PEB againstagainst•• eeffectffect ofof BMSBMS--ISRISR treatmenttreatment by PEBby PEB againstagainst11stst generationgeneration DES provedDES proved
•• PEPCAD II:PEPCAD II: signifsignif ↓ 6 M LLL, ↓ 6 M LLL, tendencytendency toto↓↓binarybinary restenosisrestenosis and MACEand MACE againstagainst PESPES
•• 22ndnd generationgeneration DESDES withwith sirolimussirolimus derivatesderivateslikelike everolimuseverolimus (EES) more(EES) more efficientefficient ininlikelike everolimuseverolimus (EES) more(EES) more efficientefficient inintreatmenttreatment ofof dede--novonovo lesionslesions
![Page 8: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/8.jpg)
![Page 9: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/9.jpg)
•• RandomizedRandomized,, prospectiveprospective trialtrial•• RandomizedRandomized,, prospectiveprospective trialtrial
•• AimAim::•• AimAim::
To compare the treatment of inin--BMstentBMstent restenosisrestenosis bydrug-eluting balloon catheters using paclitaxel (PEBPEB)drug-eluting balloon catheters using paclitaxel (PEBPEB)with 2nd generation drug-eluting stents usingeverolimus (EESEES)
![Page 10: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/10.jpg)
InclusionInclusion criteriacriteria::InclusionInclusion criteriacriteria::
•• PtsPts treatedtreated forfor BMSBMS--ISR inISR in oneone center 2012center 2012--1414
•• BMSBMS--ISR ˃50% DSISR ˃50% DS
•• InformedInformed consentconsent signedsigned
ExclusionExclusion criteriacriteria::ExclusionExclusion criteriacriteria::
•• PrognosisPrognosis < 12< 12 monthsmonths
•• LimitedLimited possibilitypossibility toto performperform controlcontrol angioangio afterafter 12 M12 M•• LimitedLimited possibilitypossibility toto performperform controlcontrol angioangio afterafter 12 M12 M((advancedadvanced renalrenal failurefailure etcetc))
•• LongLong--termterm dualdual antiplateletantiplatelet treatmenttreatment notnot possiblepossible•• LongLong--termterm dualdual antiplateletantiplatelet treatmenttreatment notnot possiblepossible
![Page 11: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/11.jpg)
•• 136136 ptspts withwith BMSBMS--ISRISR•• 136136 ptspts withwith BMSBMS--ISRISR
• 2 groups
iopromideiopromide--coatedcoated PEB (PEB (SequentSequent PleasePlease))
vs.vs.
everolimuseverolimus--elutingeluting stent (EES;stent (EES; PromusPromus,, PtPt//CrCr))
•• PrimaryPrimary endend--point:point: 12 M late lumen loss (LLL)•• PrimaryPrimary endend--point:point: 12 M late lumen loss (LLL)
•• SecondarySecondary endend--pointspoints::
12 months binary restenosis12 months binary restenosis
MACE (CV death/nonfatal MI/TVR)
•• nonnon--inferiority studyinferiority study•• nonnon--inferiority studyinferiority study
![Page 12: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/12.jpg)
![Page 13: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/13.jpg)
![Page 14: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/14.jpg)
![Page 15: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/15.jpg)
![Page 16: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/16.jpg)
•• ClinicalClinical 66 monthsmonths and 12and 12 monthsmonths visitvisit
•• 1212 monthsmonths angioangio withwith QCAQCA
![Page 17: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/17.jpg)
PEBPEB EESEES ppPEBPEB EESEES pp
PatientPatientss,, nn 6868 6868
ISRISR llesionsesions,, nn 7474 7474ISRISR llesionsesions,, nn 7474 7474
MMalesales//FemalesFemales 4343 ((63,2463,24%)%) // 2525 ((36,7436,74%)%) 4646 ((67,6567,65%)%) // 2222 ((32,3532,35%)%) 0,5890,589 ⃰⃰
Age,Age, yearsyears 65,665,6 ±±10,910,9†† 65,565,5 ±±10,610,6†† 0,9300,930††Age,Age, yearsyears 65,665,6 ±±10,910,9†† 65,565,5 ±±10,610,6†† 0,9300,930††
EjeEjectionction fractionfraction,, %% 49,7449,74 ±±11,9511,95††//50,050,0‡‡ 49,5749,57±± 11,4411,44††//50,050,0‡‡ 0,9560,956♯♯
Diabetes mellitusDiabetes mellitus 1717 ((25,0025,00%)%) 1818 ((26,4726,47%)%) 0,8440,844 ⃰⃰Diabetes mellitusDiabetes mellitus 1717 ((25,0025,00%)%) 1818 ((26,4726,47%)%) 0,8440,844 ⃰⃰
RenRenalal insufficiencyinsufficiency 22 ((2,942,94%)%) 77 ((10,2910,29%)%) 0,1650,165§§
2VD2VD//3VD3VD 3838 ((55,8855,88%)%) 4141 ((60,2960,29%)%) 0,6020,602 ⃰⃰2VD2VD//3VD3VD 3838 ((55,8855,88%)%) 4141 ((60,2960,29%)%) 0,6020,602 ⃰⃰
Multi ISRMulti ISR 44 ((5,885,88%)%) 55 ((7,357,35%)%) 1,0001,000§§
† mean ± SD; ‡ median
![Page 18: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/18.jpg)
PEBPEB EESEES pp--valuevalue
ACSACS (STEMI/NSTEMI)(STEMI/NSTEMI) 4545 ((66,1866,18%)%) 5050 ((73,5373,53%)%)ACSACS (STEMI/NSTEMI)(STEMI/NSTEMI) 4545 ((66,1866,18%)%) 5050 ((73,5373,53%)%)0,3500,350 ⃰⃰
SStabtablele APAP 2323 ((33,8233,82%)%) 1818 ((26,4726,47%)%)
LesionLesion typetype B2/CB2/C 5151 ((68,9268,92%)%) 47 (47 (63,5163,51%)%) 0,4870,487 ⃰⃰
SStenttent diameterdiameter,, mmmm 3,183,18 ±±0,430,43/3,0/3,0‡‡ 3,203,20 ±±0,410,41††//3,03,0‡‡ 0,6090,609♯♯
StentStent lengthlength,, mmmm 22,6522,65 ±±11,7011,70††//19,019,0‡‡ 19,3919,39 ±±9,279,27††//16,016,0‡‡ 0,0770,077♯♯StentStent lengthlength,, mmmm 22,6522,65 ±±11,7011,70††//19,019,0‡‡ 19,3919,39 ±±9,279,27††//16,016,0‡‡ 0,0770,077♯♯
† mean ± SD; ‡ medianmean ± SD; median
![Page 19: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/19.jpg)
PEB EES p
ACS,ACS, STEMI/NSTEMISTEMI/NSTEMI 2424 ((35,2935,29%)%) 2525 ((36,7636,76%)%) 0,0980,098 ⃰⃰
TimeTime ofof ISRISR,, mmonthsonths 12,1012,10±±8,478,47††//9,09,0‡‡ 16,5116,51±±9,499,49††//24,024,0‡‡ 0,0090,009♯♯
ISRISR:: I (I (fofocalcal)) 3030 ((40,5440,54%)%) 2121 ((28,3828,38%)%)
0,2660,266 ⃰⃰II (II (difdiffusefuse)) 3434 ((45,9545,95%)%) 3535 ((47,3047,30%)%)
III (III (proliferativproliferativee)) 55 ((6,766,76%)%) 88 ((10,8110,81%)%)
IVIV ((occlusiveocclusive)) 55 ((6,766,76%)%) 1010 ((13,5113,51%)%)IVIV ((occlusiveocclusive)) 55 ((6,766,76%)%) 1010 ((13,5113,51%)%)
CuttingCutting predilatpredilatationation 16 (16 (21,6221,62%)%) 55 ((6,766,76%)%) 0,0100,010 ⃰⃰
ISR; PEB/EESISR; PEB/EES diametdiameterer,, mmmm 3,323,32 ±±0,390,39/3,5/3,5‡‡ 3,313,31 ±±0,430,43††//3,53,5‡‡ 0,9890,989♯♯ISR; PEB/EESISR; PEB/EES diametdiameterer,, mmmm 3,323,32 ±±0,390,39/3,5/3,5‡‡ 3,313,31 ±±0,430,43††//3,53,5‡‡ 0,9890,989♯♯
ISR; PEB/EESISR; PEB/EES lengthlength,, mmmm 22,5322,53 ±±8,138,13††//20,020,0‡‡ 28,4728,47 ±±12,7612,76††//24,024,0‡‡ 0,0010,001♯♯
PostdilataPostdilatationtion,, atmatm 14,8414,84 ±±2,772,77††//16,016,0‡‡ 14,1114,11 ±±2,452,45††//12,012,0‡‡ 0,0930,093♯♯PostdilataPostdilatationtion,, atmatm 14,8414,84 ±±2,772,77††//16,016,0‡‡ 14,1114,11 ±±2,452,45††//12,012,0‡‡ 0,0930,093♯♯
22ndnd stent istent implantamplantationtion 11 (11 (14,8614,86%)%) 1111 ((14,8614,86%)%) 1,0001,000 ⃰⃰
† mean ± SD; ‡ median
![Page 20: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/20.jpg)
PEBPEB EESEES pp
PreprocedurPreproceduralal pparametarametersers::PreprocedurPreproceduralal pparametarametersers::
Minimal lumen diameter, mmMinimal lumen diameter, mm 0,920,92±±0,450,45††//1,001,00‡‡ 0,790,79±±0,480,48††//0,770,77‡‡ 0,0620,062§§
Reference diameter, mmReference diameter, mm 2,642,64±±0,470,47††//2,632,63‡‡ 2,662,66±±0,450,45††//2,662,66‡‡ 0,6720,672§§
% Diameter% Diameter stenosisstenosis 71,871,8±±13,913,9††//70,070,0‡‡ 78,078,0±±13,413,4††//76,076,0‡‡ 0,0070,007§§
PostprocedurPostproceduralal pparameterarameters:s:
Minimal lumen diameter, mmMinimal lumen diameter, mm 2,182,18±±0,390,39††//2,132,13‡‡ 2,512,51±±0,380,38††//2,492,49‡‡ <<0,00010,0001§§Minimal lumen diameter, mmMinimal lumen diameter, mm 2,182,18±±0,390,39 //2,132,13 2,512,51±±0,380,38 //2,492,49 <<0,00010,0001
Reference diameter,Reference diameter, mmmm 2,792,79±±0,410,41††//2,792,79‡‡ 3,013,01±±0,400,40††//2,962,96‡‡ 0,0060,006§§
Acute gain, mmAcute gain, mm 1,251,25±±0,540,54††/1,12/1,12‡‡ 1,721,72±±0,470,47††/1,69/1,69‡‡ << 0,00010,0001§§Acute gain, mmAcute gain, mm 1,251,25±±0,540,54 /1,12/1,12 1,721,72±±0,470,47 /1,69/1,69 << 0,00010,0001
% Diameter residual% Diameter residual stenosisstenosis 19,519,5±±7,47,4††//20,020,0‡‡ 16,316,3±±5,95,9††//16,016,0‡‡ 0,0050,005§§
![Page 21: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/21.jpg)
PEBPEB EESEES
1212--M visitM visit 6868 6868
1212--M QCAM QCA--ptspts 6363// 92,6%92,6%((95% CI: 83,7%95% CI: 83,7% --97,6%)97,6%)
62/ 91.2%62/ 91.2%(95% CI: 81.78(95% CI: 81.78––96.69)96.69)((95% CI: 83,7%95% CI: 83,7% --97,6%)97,6%) (95% CI: 81.78(95% CI: 81.78––96.69)96.69)
1212--M QCAM QCA-- lesionslesions 69/69/ 93,293,2%%((95% CI: 84,9%95% CI: 84,9% -- 97,8%)97,8%)
6868// 91,9%91,9%((95% CI: 83,2%95% CI: 83,2% -- 97%)97%)
p = 0,753p = 0,753
![Page 22: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/22.jpg)
PEBPEB EESEES pp
Minimal lumen diameter, mmMinimal lumen diameter, mm 2,092,09±±0,570,57††//2,132,13‡‡ 2,072,07±±0,800,80//††2,232,23‡‡ 0,4810,481§§Minimal lumen diameter, mmMinimal lumen diameter, mm 2,092,09±±0,570,57††//2,132,13‡‡ 2,072,07±±0,800,80//††2,232,23‡‡ 0,4810,481§§
Reference diameter, mmReference diameter, mm 2,812,81±±0,480,48††//2,812,81‡‡ 2,962,96±±0,500,50††//2,862,86‡‡ 0,1880,188§§
% Diameter% Diameter stenosisstenosis 26,226,2±±18,018,0††//22,022,0‡‡ 30,930,9±±24,624,6††//21,521,5‡‡ 0,8160,816§§
Late lumen loss, mmLate lumen loss, mm 0,090,09±±0,440,44††//0,020,02‡‡ 0,440,44±±0,730,73††//0,190,19‡‡ 0,00040,0004 §§
BinBinaryary restenosisrestenosis (%(%DS˃50%)DS˃50%) 66 ((8,78,7%)%) 13 (13 (19,1219,12%)%) 0,0780,078♯♯
§nonparametric Mann–Whitney U test
![Page 23: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/23.jpg)
PEBPEB EESEES pp §§
ISRISR lengthlength ˃10 mm˃10 mm LLLLLL (mm)(mm) 0,160,16±±0,500,50††//0,050,05‡‡ 0,530,53±±0,670,67††//0,260,26‡‡ 0,00020,0002
VesselVessel diameterdiameter ˂ 3 mm˂ 3 mm LLLLLL (mm)(mm) 0,120,12±±0,480,48††//0,050,05‡‡ 0,420,42±±0,630,63††//0,160,16‡‡ 0,0030,003VesselVessel diameterdiameter ˂ 3 mm˂ 3 mm LLLLLL (mm)(mm) 0,120,12±±0,480,48††//0,050,05‡‡ 0,420,42±±0,630,63††//0,160,16‡‡ 0,0030,003
Diabetes mellitusDiabetes mellitus LLLLLL (mm)(mm) 0,120,12±±0,330,33††//0,060,06‡‡ 0,480,48±±0,860,86††//0,120,12‡‡ 0,2540,254
![Page 24: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/24.jpg)
PEBPEB EESEES pp
MACEMACE allall 7 (7 (10,2910,29%)%) 1313 ((19,1219,12%)%) 0,2130,213§§MACEMACE allall 7 (7 (10,2910,29%)%) 1313 ((19,1219,12%)%) 0,2130,213§§
CVCV deathdeath 1 (1 (1,471,47%)%) 1 (1 (1,471,47%)%) 1,0001,000§§
NonfatalNonfatal MIMI 1 (1 (1,471,47%)%) 1 (1 (1,471,47%)%) 1,0001,000§§NonfatalNonfatal MIMI 1 (1 (1,471,47%)%) 1 (1 (1,471,47%)%) 1,0001,000§§
TVRTVR 55 ((7,357,35%)%) 11 (11 (16,1816,18%)%) 0,1100,110§§
DefiniteDefinite stentstent thrombosisthrombosis 1 (1 (1,451,45 %)%) 0 (0%)0 (0%) 1,0001,000♯♯DefiniteDefinite stentstent thrombosisthrombosis 1 (1 (1,451,45 %)%) 0 (0%)0 (0%) 1,0001,000♯♯
EventEvent--freefree survivorsurvivorss 61 (61 (89,7189,71%)%) 55 (55 (80,8880,88%)%) 0,1100,110§§
![Page 25: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/25.jpg)
•• NNonon--inferiorityinferiority but also superiority of PEB vs EESbut also superiority of PEB vs EES•• NNonon--inferiorityinferiority but also superiority of PEB vs EESbut also superiority of PEB vs EES
•• 1212 monthsmonths LLL in PEBLLL in PEB groupgroup significantlysignificantly lowerlower•• 1212 monthsmonths LLL in PEBLLL in PEB groupgroup significantlysignificantly lowerlowervsvs EESEES groupgroup
•• NoNo significantsignificant differencedifference in Binaryin Binary restenosisrestenosis andand1212 monthsmonths MACEMACE1212 monthsmonths MACEMACE
![Page 26: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/26.jpg)
•• 190190 ptspts withwith BMSBMS--ISRISR
•• iopromideiopromide--coatedcoated PEB (PEB (SequentSequent PleasePlease) vs. EES () vs. EES (XienceXience,,Co/Co/CrCr))
PEBPEB EESEES pp
Co/Co/CrCr))
•• 99--MM angioangio(QCA) and 12(QCA) and 12--MM clinicalclinical followfollow upup
PEBPEB EESEES pp
MLD, mmMLD, mm 2,01+/2,01+/-- 0,60,6 2,36 +/2,36 +/--0,60,6 p < 0,001p < 0,001
%DS%DS 25+/25+/--20%20% 13+/13+/--17%17% p < 0,001p < 0,001%DS%DS 25+/25+/--20%20% 13+/13+/--17%17% p < 0,001p < 0,001
LLL, mmLLL, mm 0,14+/0,14+/-- 0,50,5 0,04+/0,04+/-- 0,50,5 p = 0,14p = 0,14
binarybinary ISRISR 9,59,5%% 4,7%4,7% p = 0,22p = 0,22binarybinary ISRISR 9,59,5%% 4,7%4,7% p = 0,22p = 0,22
12 M12 M MACEMACE 8%8% 6%6% p = 0,6p = 0,6
![Page 27: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/27.jpg)
•• MoreMore neoatherosclerosisneoatherosclerosis
•• TreatmentTreatment ofof DESDES--ISR:ISR: worseworse resultsresults thanthan in BMSin BMS--ISRISR
•• HabaraHabara etet alal::•• HabaraHabara etet alal::
subanalysissubanalysis –– significsignific ↑ LLL (0,18 vs. 0,05mm; p = 0,03) and ↑ LLL (0,18 vs. 0,05mm; p = 0,03) and binarybinary restenosisrestenosis (9,1 vs. 1,1%, p= 0,04)(9,1 vs. 1,1%, p= 0,04) vsvs BMSBMS--ISRISR
•• SeQuentSeQuent PleasePlease WorldWorld WideWide Registry:Registry:
significsignific ↑ TLR (9,6 vs. 3,8%; p˂0,001) and MACE (11,3 vs. ↑ TLR (9,6 vs. 3,8%; p˂0,001) and MACE (11,3 vs. 5,6%;5,6%;p˂0,001) p˂0,001) vsvs BMSBMS--ISRISRp˂0,001) p˂0,001) vsvs BMSBMS--ISRISR
•• DEB ~ DESDEB ~ DES
![Page 28: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/28.jpg)
BVSBVS RestenosisRestenosis ((ScRScR))BVSBVS RestenosisRestenosis ((ScRScR))
SubanalysisSubanalysis ofof GHOSTGHOST--EU registry:EU registry:
•• 1414 ScRScR -- 3,63,6%; 60%; 60%% focalfocal, 20%, 20% diffusediffuse•• 1414 ScRScR -- 3,63,6%; 60%; 60%% focalfocal, 20%, 20% diffusediffuse
•• DueDue to:to: underexpansionunderexpansion (in(in diffusediffuse),), 1x1x geograficgeograficmissmissmissmiss
•• treatmenttreatment: 45: 45% DEB, 35% DES,% DEB, 35% DES, 15% POBA15% POBA ––NCNC postdilatationpostdilatation,, anotheranother BVSBVS (1x) 5(1x) 5%%
![Page 29: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/29.jpg)
• High minimal lumen diameter (MLD)• High minimal lumen diameter (MLD)
• PEB similar to DES
• Different types of PEB and DES• Different types of PEB and DES
• PEB better when ≥2 stent layers
• DES better when edge disease
• OCT, IVUS• OCT, IVUS
![Page 30: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/30.jpg)
![Page 31: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/31.jpg)
![Page 32: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/32.jpg)
![Page 33: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/33.jpg)
•• MostMost trialstrials -- endpointsendpoints:: TLFTLF (CV(CV deathdeath +TV+TV--•• MostMost trialstrials -- endpointsendpoints:: TLFTLF (CV(CV deathdeath +TV+TV--MI+MI+ TLR)TLR)
•• ABSORB II :ABSORB II : TLFTLF 5%5%•• ABSORB II :ABSORB II : TLFTLF 5%5%
•• ABSORB III:ABSORB III: TLFTLF 7,4% /12M7,4% /12M -- nonnon--inferiorinferior vs.vs.EESEESEESEES
•• GHOST EU registry:GHOST EU registry: TLFTLF 2,2%2,2% -- 1M and1M and 4,4%4,4%-- 6M, 16M, 1 yearyear predictionprediction -- 1010%%-- 6M, 16M, 1 yearyear predictionprediction -- 1010%%
![Page 34: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/34.jpg)
Adjusted ORAdjusted OR 95% CI95% CI pp
Diabetes mellitus (Diabetes mellitus (1=1=yesyes, 0=n, 0=noo)) 2,0452,045 0,6110,611 –– 6,8426,842 0,2460,246Diabetes mellitus (Diabetes mellitus (1=1=yesyes, 0=n, 0=noo)) 2,0452,045 0,6110,611 –– 6,8426,842 0,2460,246
RenRenalal insufficiencinsufficiencyy ((1=1=yesyes,, 0=n0=noo)) -- -- 0,9990,999
TypeType B2/CB2/C lesionlesion (1=(1=yesyes,, 0=n0=noo)) 1,6611,661 0,5280,528 –– 5,2245,224 0,3860,386TypeType B2/CB2/C lesionlesion (1=(1=yesyes,, 0=n0=noo)) 1,6611,661 0,5280,528 –– 5,2245,224 0,3860,386
PEB =1 / EES =2PEB =1 / EES =2 3,1323,132 1,0581,058 –– 9,2699,269 0,0390,039
VesselVessel diameterdiameter <3<3 mm (mm (1=1=yesyes,, 0=n0=noo)) 2,2832,283 0,5580,558 –– 9,3439,343 0,2510,251VesselVessel diameterdiameter <3<3 mm (mm (1=1=yesyes,, 0=n0=noo)) 2,2832,283 0,5580,558 –– 9,3439,343 0,2510,251
ISRISR lengthlength >10 mm (>10 mm (1=1=yesyes, 0=n, 0=noo)) 1,9751,975 0,5870,587 –– 6,6466,646 0,2720,272
![Page 35: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/35.jpg)
The 2-sided 95% confidence interval for the difference betweentreatments in LLL (0,149 - 0,558) and the non-inferiority margin (0,12)treatments in LLL (0,149 - 0,558) and the non-inferiority margin (0,12)non-inferiority but also superiority of PEB vs EES
![Page 36: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/36.jpg)
![Page 37: In stent restenosis Snowmass 2017 final final [Read-Only]...occlusive 4.2014 1 bms 8.2014 poba 9.2014 1 des 4.2015 1 des, deb 9.2015 1 des, deb 4.2016 2 deb 2.2017 2 des, deb](https://reader030.vdocuments.mx/reader030/viewer/2022041121/5f35391215cd2d4c9f6c2adc/html5/thumbnails/37.jpg)